Orforglipron | Oral GLP-1 Agonist | Small-Molecule | 99% Purity | CAS 2212020-52-3 | White Powder | Diabetes&Weight Loss

GMP ISO FDA COA 28 Inquiries

Unit Price: Get Latest Price 

CAS No.:

2212020-52-3

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Beijing

Packaging:

5g/10g/20g/50g/100g/500g/1000g

Sample Available:

Yes

Price valid (until):

2026-05-10

Contact Supplier

 Chat Now

Shandong transco international Co.,Ltd

Company Type:

Trader

Location:

China

Payment Terms:

O/A,100% TT in advance

Average Lead Time:

5 days

Qualification:

Main Products:

Tirzepatide,Semaglutide,Retatrutide,Liraglutide,Semax,Acetate

 Visit Store

Product Description
Seller Information
Inquiry History

Description
Product Detail

Orforglipron – High-Purity GLP-1 Receptor Agonist (RUO)

CAS: 2212020-52-3 | ≥99% Purity | White Powder

Orforglipron is a next-generation oral GLP-1 receptor agonist designed for advanced metabolic research. It plays a key role in studies of glucose regulation, appetite control, and energy balance pathways, making it a highly valuable compound in diabetes and obesity-related research.

Compared with traditional peptide GLP-1 analogs, Orforglipron offers improved oral activity and strong receptor selectivity, supporting more flexible experimental design in metabolic studies.

Widely used in research focusing on:
• GLP-1 receptor signaling mechanisms
• Blood glucose regulation pathways
• Obesity and weight management models
• Appetite and energy metabolism studies
• Incretin-based drug discovery research

Product Highlights:
✔ High Purity ≥99%
✔ Excellent Stability
✔ Consistent Batch Quality
✔ Scalable Production (100–200 kg)
✔ Suitable for R&D and laboratory use

Orforglipron is a key reference compound in modern incretin research and is often studied alongside advanced metabolic agents to better understand multi-pathway glucose and weight regulation systems.

⚠ Research Use Only (RUO)

Contact Us

Ms. Iris

Tel/Whatsapp：+86 13002751028

Email: Irisbian@transcoasia.com

Specifications

White powder

Purity ≥ 99%

Bacterial endotoxins: <10EU/mg

Company Introduction

ECHEMI Editorial Reference

Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.
Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.
Research & Reference Note

Orforglipron | Oral GLP-1 Agonist | Small-Molecule | 99% Purity | CAS 2212020-52-3 | White Powder | Diabetes&Weight Loss is listed on ECHEMI for industrial / laboratory sourcing. This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Authoritative sources

PubChem

ClinicalTrials.gov

FDA Drugs@FDA

NIH
Disclaimer: This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

Reviewed by ECHEMI Scientific Review - Platform editorial review for research chemicals
Certificates
Basic Info

Product Name:
Orforglipron

Other Name:
1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...;LY3502970;GLP-1 receptor agonist 1 USP/EP/BP;Orforglipron;Orforglipron（LY3502970）;LY3502970 (Orforglipron);3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;OWL 833

CAS No.:
2212020-52-3

Molecular Formula:
C48H48F2N10O5

InChIKeys:
USUWIEBBBWHKNI-BBGRWQLENA-N

Molecular Weight:
882.97

EC Number:
278-636-5

Color/Form:
Off-white to light yellow

Categories:
Hormones and the Endocrine System

Characteristics

Density:
1.50±0.1 g/cm3(Predicted)

PKA:
7.33±0.20(Predicted)

Critical Temperature & Pressure:
Store at -20°C

See More Orforglipron Properties 
Seller Information

Business Type:
Trader

Main Products:
Tirzepatide,Semaglutide,Retatrutide,Liraglutide,Semax,Acetate

Location:
Qingtie Plaza, No. 118 Changjiang West Road, Huangdao District

Payment Terms:
O/A,100% TT in advance

Average lead Time:
5 days

Total Annual Revenue:
$10 million-$25 million

Total Employees:
11-50

Year of Establishment:
2019

Inquiry History

28 Inquiries

Country	Product	Purchase Quantity	Date Posted
Bulgaria	orforglipron	1 KG	Aug 27, 2025
Austria	Orforglipron	1000 MT	Jun 12, 2026
Switzerland	Orforglipron	10 MG	Apr 25, 2026
United States	Orforglipron	20 G	Apr 3, 2026
United States	Orforglipron	10 G	Mar 29, 2026
United States	oforglipron	3 KG	Jul 4, 2025
United Kingdom	Orforglipron	1 G	Jul 9, 2026
Belgium	Orforglipron	1 G	Jun 14, 2026
Puerto Rico	Orforglipron	1 G	Mar 2, 2026
United States	Orforglipron	10 G	Oct 24, 2025
United States	Orforglipron	1 G	Sep 30, 2025
United States	Orforglipron	1 G	Sep 26, 2025
United States	Orforglipron	1 G	Sep 26, 2025
United States	orforglipron	1 MT	Sep 20, 2025
United States	Orforglipron	1 KG	Apr 18, 2025
Canada	LY-3502970	10 G	Feb 26, 2026
Switzerland	Orforglipron	100 G	Sep 25, 2026
India	orforglipron	1.00 G	Jul 16, 2026
United States	orforglipron	10 G	Apr 20, 2026
United States	Orforglipron	10 G	Apr 6, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Weight Loss 99% Orforglipron/LY3502970/LY-3502970 CAS: 2212020-52-3 Best Quality	Pharmaceutical Grade/99.9	$90-115/G FOB	Hangzhou Hyper Chemicals Limited	Inquiry
2212020-52-3 Orforglipron-LY3502970	/99	$5-6/KG FOB	Conier Chem&Pharma Limited	Inquiry
Orforglipron (high qualified)	/	$1-1.2/KG FOB	Hangzhou zhongqi chem co.,Ltd	Inquiry
High Quality 99% Purity Orforglipron Powder CAS 2212020-52-3 Raw Material for Pharmaceutical Research	Pharmaceutical Grade/99	$62-80/G FOB	Fulecare	Inquiry
High Purity Orforglipron Powder CAS 2212020-52-3 Pharmaceutical Raw Material	Pharmaceutical Grade/99	$22-23/G FOB	NATURE INDUSTRIAL LIMITED	Inquiry

Orforglipron | Oral GLP-1 Agonist | Small-Molecule | 99% Purity | CAS 2212020-52-3 | White Powder | Diabetes&Weight Loss

Product Description

Seller Information

Inquiry History

More Choices Find All Products for Sale 

Related Searches

More from this Seller

Specifications
White powder
Purity ≥ 99%
Bacterial endotoxins: <10EU/mg